UA82753C2 - Производные пролина, которые используются в качестве фармацевтических активных ингредиентов для лечения опухолей - Google Patents

Производные пролина, которые используются в качестве фармацевтических активных ингредиентов для лечения опухолей Download PDF

Info

Publication number
UA82753C2
UA82753C2 UAA200608086A UAA200608086A UA82753C2 UA 82753 C2 UA82753 C2 UA 82753C2 UA A200608086 A UAA200608086 A UA A200608086A UA A200608086 A UAA200608086 A UA A200608086A UA 82753 C2 UA82753 C2 UA 82753C2
Authority
UA
Ukraine
Prior art keywords
hydroxy
items
tumor
carcinoma
pharmaceutical agent
Prior art date
Application number
UAA200608086A
Other languages
English (en)
Ukrainian (uk)
Inventor
Цозер Б. Салама
Original Assignee
Цозер Б. Салама
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Цозер Б. Салама filed Critical Цозер Б. Салама
Publication of UA82753C2 publication Critical patent/UA82753C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к производным пролина и их солей, к фармацевтическим средствам, которые содержат указанные производные, и к использованию указанных средств для лечения опухолей. Изобретение относится также к способам получения указанных соединений и фармацевтических средств.
UAA200608086A 2003-12-18 2003-12-18 Производные пролина, которые используются в качестве фармацевтических активных ингредиентов для лечения опухолей UA82753C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/DE2003/004211 WO2005058816A1 (de) 2003-12-18 2003-12-18 Prolinderivate als pharmazeutische wirkstoffe in der tumortherapie

Publications (1)

Publication Number Publication Date
UA82753C2 true UA82753C2 (ru) 2008-05-12

Family

ID=34683207

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200608086A UA82753C2 (ru) 2003-12-18 2003-12-18 Производные пролина, которые используются в качестве фармацевтических активных ингредиентов для лечения опухолей

Country Status (10)

Country Link
US (1) US20080176923A1 (ru)
EP (1) EP1711462A1 (ru)
JP (1) JP2007523829A (ru)
CN (1) CN1942438A (ru)
AU (1) AU2003298077A1 (ru)
BR (1) BR0318659A (ru)
CA (1) CA2548391A1 (ru)
MX (1) MXPA06007007A (ru)
UA (1) UA82753C2 (ru)
WO (1) WO2005058816A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120495A1 (en) 2004-06-14 2005-12-22 Salama Zoser B Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody
CN100396666C (zh) * 2005-12-14 2008-06-25 郑州大学 （4s）-1-叔丁氧羰基-4-氨基-l-脯氨酸乙酯及其合成工艺
WO2012024367A2 (en) * 2010-08-18 2012-02-23 Del Mar Pharmaceuticals Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol
US10201521B2 (en) * 2012-01-20 2019-02-12 Del Mar Pharmaceuticals (Bc) Ltd. Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem and cancer stem cells including glioblastoma multiforme and medulloblastoma
WO2013169600A1 (en) 2012-05-09 2013-11-14 Delmar Pharmaceuticals Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies
EA030611B1 (ru) * 2013-03-15 2018-08-31 Кэнсер Рисерч Текнолоджи, Ллк Способы и композиции для модуляции гамма-глутамилового цикла
US10328051B2 (en) * 2014-09-22 2019-06-25 Zoser B. Salama Proline or proline derivatives for the treatment of dementia
CN105061282A (zh) * 2015-07-28 2015-11-18 黑龙江省科学院石油化学研究院 氢解合成α,α-二苯基-2-吡咯烷甲醇的方法
AU2020349967A1 (en) * 2019-09-20 2022-05-12 Michiko Koga Peptide, and cell fusion agent and pharmaceutical composition for cancer therapy containing said peptide
CN113968808B (zh) * 2021-11-26 2024-04-09 河南中医药大学 一类水苏碱衍生物的制备方法及其应用
CN114028388B (zh) * 2021-12-16 2023-05-12 郑州大学第一附属医院 脯氨酸在制备肺癌治疗药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499287A (en) * 1981-02-02 1985-02-12 E. R. Squibb & Sons, Inc. Certain-4-hydroxy-proline derivatives
CA1281288C (en) * 1984-11-05 1991-03-12 Wilhelm Hoerrmann Tumor therapy
DE3518078A1 (de) * 1985-05-20 1986-11-20 Wilhelm Dr. 8127 Iffeldorf Hoerrmann Arzneimittel, die derivate des prolin oder hydroxyprolin enthalten
JPH05213957A (ja) * 1992-02-07 1993-08-24 Tsumura & Co 新規なスピロピロリジンイミダゾリン誘導体および新規なアミノピロリジンカルボン酸誘導体並びに該化合物を有効成分とする鎮けい剤
WO1997033578A1 (de) * 1996-03-11 1997-09-18 Wilhelm Hoerrmann Kombination aus cis-4-hydroxy-l-prolin und n-methyl-cis-4-hydroxy-l-prolin zur anwendung als therapeutischer wirkstoff insbesondere für die krebstherapie
AU2002227020A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists

Also Published As

Publication number Publication date
CN1942438A (zh) 2007-04-04
EP1711462A1 (de) 2006-10-18
JP2007523829A (ja) 2007-08-23
AU2003298077A1 (en) 2005-07-05
BR0318659A (pt) 2006-11-28
CA2548391A1 (en) 2005-06-30
US20080176923A1 (en) 2008-07-24
WO2005058816A1 (de) 2005-06-30
AU2003298077A2 (en) 2005-07-05
MXPA06007007A (es) 2007-06-08

Similar Documents

Publication Publication Date Title
ES2402791T3 (es) Forma cristalina de la sal diclorhidrato de ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo
US8338606B2 (en) Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
UA82753C2 (ru) Производные пролина, которые используются в качестве фармацевтических активных ингредиентов для лечения опухолей
US11389459B2 (en) Texaphyrin-Pt(IV) conjugates and compositions for use in overcoming platinum resistance
US10010520B2 (en) Combined application of isothiocyanate compound and anti-cancer medicine
US20070207980A1 (en) Chp-gemcitabine Combination Agents And Their Use As Anti-Tumor Agents
US7732485B2 (en) Treatment of cancer
US20080039483A1 (en) Novel Chelidonine Derivatives, Methods for the Production Thereof, and Use Thereof For Producing Pharmaceutical Agents
MXPA06003843A (es) Metodo para la preparacion de trans- o cis-diamoniodiclorodihidroxoplatino (iv) y el uso del mismo en la produccion de sustancias farmaceuticas activas.
KR20060103530A (ko) 종양 치료를 위한 제약학적 활성 성분으로 이용되는 프롤린유도체
KR20080034130A (ko) 항종양 화합물
CN102702297A (zh) 胆酸-萘酰亚胺类化合物的制备方法
CN114929664B (zh) 基于氨氧基酸的抗癌干细胞化合物及其方法
US20230416196A1 (en) Dimer of biguanidines and their therapeutic uses
CN102690313B (zh) 胆酸-萘酰亚胺类化合物及其应用
US20240226096A1 (en) Treatment of myeloproliferative diseases and disorders with inhibitors of bet family bdii bromodomain
CA2716288A1 (en) Copper-organic complexes, use thereof as antitumor agents and for protecting healthy tissue from ionizing radiation
US20090105206A1 (en) Copper Melphalan And Copper Tegafur As Anti-Tumor Agents
AU2013231052B2 (en) Crystalline forms of n-(tert-butoxycarbonyl)-3-methyl-l-valyl-(4r)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-n-((1r,2s)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-l-prolinamide
WO2017116049A1 (ko) 설폰아마이드계 화합물을 유효성분으로 포함하는 암의 치료 및 전이 억제용 약학적 조성물